[1] Gupta V, Eapen M, Brazauskas R, Carreras J, Aljurf M, Gale RP, Hale GA, Ilhan O, Passweg JR, Ringdén O, Sabloff M, Schrezenmeier H, Socié G, Marsh JC. Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. Haematologica, 2010, 95: 2119-2125.
[2] Passweg JR, Marsh JC. Aplastic anemia: first-line treatment by immunosuppression and sibling marrow transplantation. Hematologyamerican Society of Hematology education Program, 2010, 2010: 36-42.
[3] Bhatnagar N, Wynn R, Velangi M, et al. Upfront Matched and Mismatched Unrelated Transplantation in Paedlatric Aplastic Anaemia: A United KindomMulticentre Retrospective Experience; proceedings of the 40th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation, F, 2014. Bone Marrow Transplantation.
[4] Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A, Hillmen P, Ireland R, Kulasekararaj A, Mufti G, Snowden JA, Samarasinghe S, Wood A, Marsh JC. British Society for Standards in Haematology. Guidelines for the diagnosis and management of adult aplastic anaemia. British Journal of Haematology, 2016, 172: 187-207.
[5] Locasciulli A, Oneto R, Bacigalupo A, Socié G, Korthof E, Bekassy A, Schrezenmeier H, Passweg J, Führer M; Severe Aplastic Anemia Working Party of the European Blood and Marrow Transplant Group.Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EHSCT). Haematologica, 2007, 92: 11-8.
[6] Dezern AE, Brodsky RA. Clinical management of aplastic anemia. Expert Review of Hematology, 2011, 4: 221-230.
[7] Ellis RJ, Kahn Q, Skikne BS, Mayo MS, Allgood JW, Bodensteiner DM, Deauna-Limayo D, Cook JD. A retrospective analysis of long-term survival in severe aplastic anemia patients treated with allogeneic bone marrow transplantation or immunosuppressive therapy with antithymocyte globulin and cyclosporin A at a single institution. Military Medicine, 2002,167: 541–545.
[8] Bacigalupo A, Hows J, Gluckman E, Nissen C, Marsh J, et al. Bone marrow transplantation (HSCT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EHSCT SAA working party. Br J Haematol, 1988, 70: 177–182.
[9] Arranz R, Otero MJ, Ramos R, Steegmann JL, Lamana ML, Tomás JF, de la Cámara R, Figuera A, Vázquez L, Fernádez-Rañada JM. Clinical results in 50 multiply transfused patients with severe aplastic anemia treated with bone marrow transplantation or immunosuppressive therapy. Bone Marrow Transplantation, 1994, 13:383-387.
[10] George B, Mathews V, Viswabandya A, Abraham A, Ganapule A, Fouzia NA, Korula A, Lakshmi KN, Chandy M, Srivastava A. Immunosuppressive Therapy and Bone Marrow Transplantation for Aplastic Anaemia--The CMC Experience. J Assoc Physicians India, 2015, 63(3 Suppl):36-40.
[11] Ahn MJ, Choi JH, Lee YY, Choi IY, Kim IS, Yoon SS, Park SY, Kim BK, Suh C, Son HJ, Jung CW, Lee JH, Sung JM, Im SA, Oh D, Jung SY, Yoon HJ, Cho KS, Lee JA, Yuh YJ, Kim SR, Ki M. Outcome of adult severe or very severe aplastic anemia treated with immunosuppressive therapy compared with bone marrow transplantation: multicenter trial. Int J Hematol,2003,78:133-8.
[12] Bacigalupo A, Giammarco S, Sica S. Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia. International Journal of Hematology, 2016, 104:168-174.
[13] Doney K, Leisenring W, Storb R, Appelbaum FR. Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Seattle Bone Marrow Transplant Team. Ann Intern Med, 1997, 126: 107–115.
[14] Viollier R, Passweg J, Gregor M, Favre G, Kühne T, Nissen C, Gratwohl A, Tichelli A. Quality adjusted survival analysis shows differences in outcome after immunosuppression or bone marrow transplantation in aplastic anemia. Ann Hematol, 2005, 84: 47–55.
[15] Kim I, Yoon SS, Park S, Kim BK, Kim NK. The treatment of severe aplastic anemia: outcomes of bone marrow transplantation and immunosuppressive therapy in a single institution of Korea. J Korean Med Sci, 2003, 18: 365–371.
[16]DE Planque MM, Richel DJ, Fibbe WE, den Ottolander GJ, Guiot HF, Zwaan FE. Acquired severe aplastic anaemia in adults–a single centre study with 13 years follow-up. Neth J Med, 1990, 37: 103–110.
[17] Peinemann F, Grouven U, Kröger N, Bartel C, Pittler MH, Lange S. First-Line Matched Related Donor Hematopoietic Stem Cell Transplantation Compared to Immunosuppressive Therapy in Acquired Severe Aplastic Anemia. Plos One, 2011, 6:e18572
[18] Marsh J. Making Therapeutic Decisions in Adults with Aplastic Anemia. Hematology Am Soc Hematol Educ Program, 2006:78-85.
[19] Prica A, Chan K, Cheung M C. Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system lymphoma: a cost-effectiveness analysis. British Journal of Haematology, 2012, 158:600-607.